Swedish Orphan Biovitrum AB (SE:SOBI)
:SOBI
Want to see SE:SOBI full AI Analyst Report?
SOBI Stock Chart & Stats
kr388.60
-kr5.60(-1.80%)
At close: 4:00 PM EST
kr388.60
-kr5.60(-1.80%)
Day’s Range― - ―
52-Week Rangekr261.20 - kr432.80
Previous CloseN/A
Volume57.50K
Average Volume (3M)396.16K
Market Cap
kr137.47B
Enterprise Valuekr163.30B
Total Cash (Recent Filing)kr940.00M
Total Debt (Recent Filing)kr19.06B
Price to Earnings (P/E)239.7
Beta1.14
Next Earnings
Jul 21, 2026EPS Estimate
3.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.81
Shares Outstanding357,412,840
10 Day Avg. Volume356,894
30 Day Avg. Volume396,160
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr486.67Price Target Upside25.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)17.21
Revenue Forecast (FY)kr31.61B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSobi’s operating and free cash flow being solidly positive on a TTM basis indicates the business converts sales into cash reliably. Free cash flow close to reported net income suggests earnings are largely cash-backed, supporting durable funding for R&D, launches, and partnerships without immediate financing needs.
Manageable Leverage And Balance-sheet FlexibilityLow debt-to-equity and sizable equity relative to assets give Sobi financial flexibility to invest in lifecycle management, pursue selective in-licensing, or weather market setbacks. A generally sound balance sheet supports multi-month strategic execution and reduces refinancing risk for near-term programs.
Sustained Revenue Growth (TTM)Consistent TTM revenue growth reflects continued demand for Sobi’s specialty rare-disease medicines and effective commercial coverage. Top-line momentum underpins long-term product lifecycle strategies, supports margin recovery potential, and funds ongoing international expansion and partner deals over the coming months.
Bears Say
Very Low Returns On EquityPersistently low ROE signals the company is generating limited profit from shareholders' capital, which can constrain reinvestment returns and make it harder to justify growth spending. Over a multi-month horizon, low ROE can limit strategic options and pressure capital-allocation priorities.
Net Profit Margin CompressionA sharp decline in net profit margin indicates profitability is being eroded by non-operating costs or one-offs; this reduces retained earnings and weakens resilience to shocks. If these drivers persist, they will materially limit free cash flow expansion and the ability to scale commercial or R&D initiatives over months.
Recent Decline And Volatility In Free Cash FlowAlthough cash conversion is a strength, a recent decline and past episodes of negative FCF introduce uncertainty around funding predictability. Volatile free cash flow can force trade-offs between capex, licensing deals, or debt reduction, and may impair consistent support for launches and lifecycle investments over the medium term.
Swedish Orphan Biovitrum AB News
SOBI FAQ
What was Swedish Orphan Biovitrum AB’s price range in the past 12 months?
Swedish Orphan Biovitrum AB lowest stock price was kr261.20 and its highest was kr432.80 in the past 12 months.
What is Swedish Orphan Biovitrum AB’s market cap?
Swedish Orphan Biovitrum AB’s market cap is kr137.47B.
When is Swedish Orphan Biovitrum AB’s upcoming earnings report date?
Swedish Orphan Biovitrum AB’s upcoming earnings report date is Jul 21, 2026 which is in 82 days.
How were Swedish Orphan Biovitrum AB’s earnings last quarter?
Swedish Orphan Biovitrum AB released its earnings results on Apr 28, 2026. The company reported kr3.81 earnings per share for the quarter, beating the consensus estimate of kr3.633 by kr0.177.
Is Swedish Orphan Biovitrum AB overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum AB’s price is currently Undervalued.
Does Swedish Orphan Biovitrum AB pay dividends?
Swedish Orphan Biovitrum AB does not currently pay dividends.
What is Swedish Orphan Biovitrum AB’s EPS estimate?
Swedish Orphan Biovitrum AB’s EPS estimate is 3.02.
How many shares outstanding does Swedish Orphan Biovitrum AB have?
Swedish Orphan Biovitrum AB has 357,412,840 shares outstanding.
What happened to Swedish Orphan Biovitrum AB’s price movement after its last earnings report?
Swedish Orphan Biovitrum AB reported an EPS of kr3.81 in its last earnings report, beating expectations of kr3.633. Following the earnings report the stock price went up 1.204%.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum AB?
Currently, no hedge funds are holding shares in SE:SOBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
SOBI Stock 12 Month Forecast
Average Price Target
kr486.67
▲(25.24% Upside)
Technical Analysis
Orexo AB
―
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―
Options Prices
Currently, No data available
---